Korean J Pancreas Biliary Tract.  2016 Oct;21(4):185-190. 10.15279/kpba.2016.21.4.185.

Novel Therapeutic Modalities for Metastatic Pancreatic Cancer

Affiliations
  • 1Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. bang7028@yuhs.ac

Abstract

Pancreatic cancer is still one of the most devastating cancers with less than 5% of 5-year survival even though the advances in modern medicine. Considering effective screening strategies and vaccinations has been improving clinical outcomes in other gastrointestinal malignancies, there is not yet effective tools for pancreatic cancer in earlier stage. Thus, about 80% of patients of pancreatic cancer are diagnosed as unsuitable for curative resection. Furthermore, recent experimental data suggest metastasis of pancreatic cancer can be developed in remarkably earlier stage during carcinogenesis. Based on these findings, systemic chemotherapy is the main therapeutic option for treating pancreatic cancer. However, the outcome of systemic chemotherapy is still disappointing even though recent data with FOLFIRINOX and nab-paclitaxel showed relatively promising. With advances in molecular technologies including next generation sequencing, the therapeutic paradigm for handling malignancies has been rapidly changing. The new wave of tailored or precision medicine leads to develop several novel therapeutic options like immune check point inhibitor or novel adoptive cell therapy. Herein, we will discuss the current status and perspectives of targeted therapy for pancreatic cancer.

Keyword

Pancreatic cancer; Targeted therapy; Chemotherapy
Full Text Links
  • KJPBT
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr